BRAVECTO PLUS 112.5 MG5.6 MG SPOT-ON SOLUTION VETERINARY FOR CATS

País: Israel

Idioma: anglès

Font: Ministry of Health

ingredients actius:

FLURALANER; MOXIDECTIN

Disponible des:

INTERVET ( ISRAEL) LTD

formulario farmacéutico:

SPOT-ON SOLUTION

Composición:

MOXIDECTIN 14 MG / 1 ML; FLURALANER 280 MG / 1 ML

Vía de administración:

TOPICAL

tipo de receta:

Required

Fabricat per:

PATHEON MANUFACTURING SERVICES LLC , USA

indicaciones terapéuticas:

For cats with, or at risk from, mixed parasitic infestations by ticks and fleas, gastrointestinal nematodes or heartworm. The veterinary medicinal product is exclusively indicated when use against ticks or fleas and one or more of the other target parasites is indicated at the same time. For the treatment of tick and flea infestations in cats providing immediate and persistent flea (Ctenocephalides felis) and tick (Ixodes ricinus) killing activity for 12 weeks. Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance. The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).For the treatment of infections with intestinal roundworm (4th stage larvae, immature adults and adults of Toxocara cati) and hookworm (4th stage larvae, immature adults and adults of Ancylostoma tubaeforme). For the prevention of heartworm disease caused by Dirofilaria immitis for 8 weeks.

Data d'autorització:

2021-12-22

Informació per a l'usuari

CONSUMER PACKAGE LEAFLET FOR VETERINARY MEDICINAL PRODUCT
The medicine is dispensed with a veterinarian's prescription only
For animal use only
1. NAME OF THE VETERINARY MEDICINAL PRODUCT, ITS FORM AND STRENGTH:
Bravecto Plus 112.5 mg/5.6 mg spot-on solution veterinary for Cats
Bravecto Plus 250 mg/12.5 mg spot-on solution veterinary for Cats
Bravecto Plus 500 mg/25 mg spot-on solution veterinary for Cats
Solution for topical (spot-on) use.
2. ACTIVE INGREDIENTS:
Each 1 ml of solution contains 280 mg fluralaner and 14 mg moxidectin.
Each pipette delivers:
BRAVECTO PLUS SPOT-ON SOLUTION
PIPETTE CONTENT
(ML)
FLURALANER
(MG)
MOXIDECTIN
(MG)
for small cats 1.2 – 2.8 kg
0.4
112.5
5.6
for medium-sized cats >2.8 – 6.25 kg
0.89
250
12.5
for large cats >6.25 – 12.5 kg
1.79
500
25
EXCIPIENT(S):
Butylhydroxytoluene 1.07 mg/ml
A full list of excipients is detailed in section 13 – "Additional
information".
3. WHAT IS THE MEDICINAL PRODUCT INTENDED FOR:
For cats with, or at risk from, mixed parasitic infestations by ticks
and fleas, gastrointestinal
nematodes or heartworm. The veterinary medicinal product is
exclusively indicated when use
against ticks or fleas and one or more of the other target parasites
is indicated at the same
time.
For the treatment of tick and flea infestations in cats providing
immediate and persistent flea
(_Ctenocephalides felis_) and tick (_Ixodes ricinus_) killing activity
for 12 weeks.
Fleas and ticks must attach to the host and commence feeding in order
to be exposed to the
active substance.
The product can be used as part of a treatment strategy for flea
allergy dermatitis (FAD).
For the treatment of infections with intestinal roundworm (4
th
stage larvae, immature adults
and adults of _Toxocara cati_) and hookworm (4
th
stage larvae, immature adults and adults of
_Ancylostoma tubaeforme_).
For the prevention of heartworm disease caused by _Dirofilaria
immitis_ for 8 weeks.
Therapeutic group: Antiparasitic.
4. CONTRAINDICATIONS:
Do not use in case of hypersensitivity to the active substan

Fitxa tècnica

1
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Bravecto Plus 112.5 mg / 5.6 mg spot-on solution Veterinary for cats
Bravecto Plus 250 mg / 12.5 mg spot-on solution Veterinary for cats
Bravecto Plus 500 mg / 25 mg spot-on solution Veterinary for cats
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Each ml of solution contains 280 mg fluralaner and 14 mg moxidectin.
Each pipette delivers:
BRAVECTO PLUS SPOT-ON SOLUTION
PIPETTE CONTENT (ML)
FLURALANER
(MG)
MOXIDECTIN
(MG)
for small cats 1.2 – 2.8 kg
0.4
112.5
5.6
for medium-sized cats >2.8 – 6.25 kg
0.89
250
12.5
for large cats >6.25 – 12.5 kg
1.79
500
25
EXCIPIENT(S):
Butylhydroxytoluene 1.07 mg/ml
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Spot-on solution.
Clear colourless to yellow solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For cats with, or at risk from, mixed parasitic infestations by ticks
and fleas, gastrointestinal
nematodes or heartworm. The veterinary medicinal product is
exclusively indicated when use against
ticks or fleas and one or more of the other target parasites is
indicated at the same time.
For the treatment of tick and flea infestations in cats providing
immediate and persistent flea
(
_Ctenocephalides felis_
) and tick (
_Ixodes ricinus) _
killing activity for 12 weeks. Fleas and ticks must
attach to the host and commence feeding in order to be exposed to the
active substance.
2
The product can be used as part of a treatment strategy for flea
allergy dermatitis (FAD).
For the treatment of infections with intestinal roundworm (4
th
stage larvae, immature adults and adults
of
_Toxocara cati_
) and hookworm (4
th
stage larvae, immature adults and adults of
_Ancylostoma _
_tubaeforme_
).
For the prevention of heartworm disease caused by
_Dirofilaria immitis_
for 8 weeks.
4.3
CONTRAINDICATIONS
Do not use in case of hypersensitivity to the active substance or to
any of the excipients listed in
sec